ASM commented on an FDA proposal to reclassify antigen based rapid influenza virus antigen detection test systems intended to detect influenza virus directly from clinical specimens.
The ASM sent a statement to ASM members on Dual Use Research of Concern and Biosafety.
The ASM sent the following statement to ASM members regarding the recent biosafety lapses.
The ASM sent a letter to Senator Tom Harkin thanking him for the Accelerating Biomedical Research Act and his leadership regarding funding for the National Institutes of Health.
ASM provided comments to the Centers for Medicare & Medicaid Services (CMS) regarding Section 1834A, “Improving Policies for Clinical Diagnostic Laboratory Tests,” added to the Social Security Law by the Protecting Access to Medicare Act of 2014 (PAMA).
The ASM presented recommendations to the Centers for Medicare & Medicaid Services at its annual public meeting on payment levels for new tests to be included in the 2015 Clinical Laboratory Fee Schedule.
The June issue of the Clinical Microbiology Issues Update has been published by the Office of Public Affairs.
The content of this page is restricted to ASM Members only.
Please login at the top-right or to become a member, join ASM.
The ASM sent a letter to the House Science, Space and Technology Committee regarding the DOE authorization bill that would make significant cuts in R&D funding for the energy and environmental sciences.
Ronald Atlas, Ph.D., Chair of the Public and Scientific Affairs Board testified before the Federal Experts Security Advisory Panel.
The ASM joined 50 other organizations in a campaign to highlight Closing the Innovation Deficit.